Overview

Encorafenib + Cetuximab Beyond Progression in Combination With FOLFIRI in Patients With BRAF V600E Mutated Metastatic Colorectal Cancer Progressing on Encorafenib + Cetuximab.

Status:
RECRUITING

Trial end date:
2026-06-30

Target enrollment:

Participant gender:

Summary

The aim of this study is to determine the activity of encorafenib plus cetuximab in combination with FOLFIRI in patients with BRAF V600E mutated metastatic colorectal cancer progressing on encorafenib plus cetuximab administered in second line.

Phase:

PHASE2

Details

Lead Sponsor:

Fondazione Policlinico Universitario Agostino Gemelli IRCCS

Collaborator:

Pierre Fabre Pharma GmbH

Treatments:

Cetuximab
encorafenib
IFL protocol